Physician profile
Unknown Adityanjee
NPI 1174677389
$85,210.42
in general payments reported to CMS, 2019-2025
26 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,822 · 2020: $1,390 · 2021: $2,595 · 2022: $12K · 2023: $28K · 2024: $21K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Food and Beverage: $11K · Consulting Fee: $5,738 · Travel and Lodging: $4,661 · Honoraria: $900 · Education: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,439.00 |
| Food and Beverage | $11,189.50 |
| Consulting Fee | $5,738.00 |
| Travel and Lodging | $4,660.83 |
| Honoraria | $900.00 |
| Education | $311.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $38,774.18 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $30,026.06 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $2,315.24 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $2,057.75 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $1,943.31 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $1,872.20 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $1,716.06 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,294.12 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $1,085.45 | 2020-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $961.03 | 2022-2025 | Auvelity |
| Neuronetics, INC. | $732.52 | 2019-2022 | |
| Indivior INC. | $699.36 | 2019-2025 | Sublocade, Perseris |
| E.R. Squibb & Sons, L.L.C. | $536.07 | 2024-2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $286.04 | 2019-2025 | Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $192.24 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $156.74 | 2024-2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $138.92 | 2022-2025 | Trintellix |
| Acadia Pharmaceuticals INC | $131.12 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $55.00 | 2025 | Yorvipath |
| Sage Therapeutics, LLC | $45.44 | 2025 | Zurzuvae |
| Almatica Pharma LLC | $44.07 | 2022 | |
| Eisai INC. | $40.42 | 2021 | |
| Avanir Pharmaceuticals, INC. | $35.62 | 2019-2022 | |
| Corium, LLC | $28.78 | 2023 | Azstarys |
| Braeburn INC. | $25.91 | 2023 | Brixadi |
| Noven Therapeutics, LLC | $16.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Unknown Adityanjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.